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Itch (pruritis) and pain represent two distinct sensory modalities; yet both have evolved to
alert us to potentially harmful external stimuli. Compared with pain, our understanding of itch
is still nascent. Here, we report a new clinical case of debilitating itch and altered pain
perception resulting from the heterozygous de novo p.L811P gain-of-function mutation in
NaV1.9, a voltage-gated sodium (NaV) channel subtype that relays sensory information from
the periphery to the spine. To investigate the role of NaV1.9 in itch, we developed a mouse
line in which the channel is N-terminally tagged with a fluorescent protein, thereby enabling
the reliable identification and biophysical characterization of NaV1.9-expressing neurons.
We also assessed NaV1.9 involvement in itch by using a newly created NaV1.9–/– and
NaV1.9L799P/WT mouse model. We found that NaV1.9 is expressed in a subset of
nonmyelinated, nonpeptidergic small-diameter dorsal root ganglia (DRGs). In WT DRGs,
but not those of NaV1.9–/– mice, pruritogens altered action potential parameters and NaV
channel gating properties. Additionally, NaV1.9–/– mice exhibited a strong reduction in acute
scratching behavior in response to pruritogens, whereas NaV1.9L799P/WT mice displayed
increased spontaneous scratching. Altogether, our data suggest an important contribution of
NaV1.9 to itch signaling.
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Introduction
The somatosensory nervous system detects sensory modalities 
such as pain, itch, and temperature sensitivity and transfers them 
from the periphery to the spinal cord and eventually to the sen-
sory cortex in the brain (1). Of these signals, itch (pruritis) has 
evolved to alert us to potentially dangerous external stimuli (2, 
3). Although acute itch may guard against environmental threats, 
pathological itch is a distressing physical sensation and can dra-
matically affect quality of life. Yet, compared with other senso-
ry modalities, itch is much less understood. Histamine was the 
first compound discovered to elicit itch by activating a subset of 
peripheral sensory neurons (pruriceptors) (4–6). Later, additional 
receptors were identified as key players in mediating itch sensa-
tion. The discovery of Mas-related G protein–coupled receptors 
(Mrgprs) as critical contributors to itch helped identify potential 
itch-selective neurons (7). The 4 families of histamine-indepen-
dent Mrgprs (MrgprA–D) can be activated by pruritic compounds 
such as chloroquine (CQ) and BAM8-22 and are expressed in tri-
geminal ganglia and dorsal root ganglia (DRGs) (8–10). Although 
these receptors and others have been established as initial detec-
tors of pruritic stimuli (11–16), the downstream mechanisms 
involved in mediating itch are still poorly understood.
Although voltage-gated Na+ channels (NaV1.1–NaV1.9) are crit-
ical for the propagation of action potentials (APs) (17) in sensory 
neurons, little is known about how they contribute to the trans-
mission of pruritic stimuli. Specifically, the relationship between 
NaV1.7, NaV1.8, and NaV1.9 and pain has been studied extensively, 
with knockout mouse models for all 3 channels showing effects 
in various pain assays (18–27). However, the contribution of these 
and other NaV channel subtypes to itch has yet to be explored.
Here, we report a new clinical case of unbearable itch and dis-
torted pain sensation stemming from the heterozygous de novo 
p.L811P mutation in NaV1.9 channels, encoded by the SCN11A 
gene. This mutation was previously published in relation to sev-
eral cases of complete insensitivity to pain in which abnormal 
NaV1.9 function was thought to result in nociceptor depolariza-
tion and subsequent conduction block (22, 28). Although there 
is a consensus that NaV1.9 contributes to pain (20, 29, 30), the 
role of this NaV channel subtype and the p.L811P+/WT mutation 
in itch is unknown (31). Compared with other NaV channel sub-
types, the expression patterns, functional properties, and phar-
macological sensitivities of NaV1.9 are less defined. To inves-
tigate the role of NaV1.9 in itch, we assessed its functional role 
in new mouse models in which channel expression was spatio-
temporally manipulated. We also tagged NaV1.9 with a fluores-
cent reporter to facilitate reliable identification and biophysical 
characterization of NaV1.9-expressing cells. We found that the 
channel is present in a subset of nonmyelinated, nonpeptider-
gic small-diameter DRGs. In WT DRGs but not in NaV1.9–/– mice, 
pruritogens altered AP parameters and NaV channel gating prop-
erties. Compared with control animals, NaV1.9–/– mice displayed 
reduced scratching behavior upon application of histamine, CQ, 
and BAM8-22. Combined with the observation that disease- 
related L799P/WT mice exhibited amplified scratching behav-
ior in rest conditions, our data provide compelling evidence for 
NaV1.9 participation in itch.
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vator–mediated (tTA-mediated) overexpression and (b) tetracy-
cline-controlled transcriptional silencer–mediated (tTS-mediated) 
conditional knockdown (Figure 1B).
By crossing sfGFP-NaV1.9 FAST mice (C57BL/6J) with a glob-
al Cre mouse (B6.C-Tg(CMV-cre)1Cgn; The Jackson Laboratory), we 
obtained a line in which endogenous NaV1.9 was N-terminally 
fused to sfGFP. As seen in Figure 1C, a subset of dissociated DRGs 
displayed robust fluorescence signal that overlapped with a GFP 
antibody, whereas WT tissue only showed weak background flu-
orescence. Biochemical analysis of DRGs showed the presence 
of a GFP+ band at the appropriate size for sfGFP-tagged NaV1.9, 
which was not observed in either WT or FAST cassette–containing 
mouse DRGs (Figure 1D). Correspondingly, quantitative reverse 
transcriptase PCR (RT-qPCR) did not detect NaV1.9 RNA in DRGs 
of FAST mice. Blotting for GFP and then stripping and reprobing 
of the Western blot with an NaV1.9 antibody (38) revealed a posi-
tive band in both DRGs and trigeminal ganglia. Aside from these 
tissues, NaV1.9 expression was not observed in the brain or other 
major organs (Figure 1E).
After confirming expression of fluorescence, we next sought to 
determine whether the gating properties of sfGFP-tagged NaV1.9 
were altered when compared with nontagged NaV1.9. Patch-clamp 
recordings from fluorescent sensory neurons in the presence of 
tetrodotoxin (TTX) and CsF in the patch pipette revealed a func-
tional sfGFP-NaV1.9 channel with WT gating behavior and kinet-
ics as reported in the literature (refs. 21, 22, 24, 39–43; and Supple-
mental Figure 1; supplemental material available online with this 
article; https://doi.org/10.1172/JCI122481DS1).
To further validate proper channel function, we constructed 
mouse WT NaV1.9 and sfGFP-NaV1.9 stable rodent DRG-derived 
ND7/23 cell lines by combining the Flp recombination target–
based (FRT-based) Flp-In system (Thermo Fisher Scientific) with 
intron-mediated enhancement of gene expression, a technique 
that leads to increased accumulation of mRNA and protein rela-
tive to unaltered cDNA (44). An additional benefit of this approach 
was the reduction of unwanted rearrangement events when 
propagating NaV channel cDNA in bacteria. The mouse SCN11a 
gene is encoded by 24 exons with known exon/intron boundar-
ies (45). Although we did not obtain sufficient expression with 
mouse cDNA lacking an endogenous intron or with the addition 
of C-terminal GFP (46), we consistently saw NaV1.9 current with 
cDNA containing intron 2 that increased after differentiation of 
the ND7/23 cells in medium containing NGF (100 ng/ml) and 1% 
FBS (Figure 1, F and G). RT-PCR and sequencing confirmed the 
correct excision of intron 2 to form mature channels (45). Patch-
clamp recordings from these cells showed sfGFP-NaV1.9 and WT 
channel currents with virtually identical gating properties and 
kinetics (Figure 1, H–J).
NaV1.9 is predominantly expressed in nonmyelinated small- 
diameter DRGs. We exploited the sfGFP tag to determine NaV1.9 
expression in mouse DRG subtypes. Using IHC with a GFP anti-
body, we found that all sfGFP+ cells overlapped with peripherin, 
a marker for peripheral sensory neurons (Figure 2A). We also 
observed strong overlap between sfGFP and IB4 (Figure 2B; 
86%) and c-Ret (Figure 2C; 89%), 2 markers for small-diameter, 
unmyelinated nonpeptidergic fibers. We detected a small portion 
of sfGFP+ cells that overlapped with calcitonin gene–related pep-
Results
A newly identified NaV1.9L799P/WT patient. Whole-exome sequencing 
uncovered the de novo p.L811P (c.T2432C) mutation in NaV1.9 in 
a female patient reporting severe pruritus without a family histo-
ry. In addition to itch, the patient reported a partial loss-of-pain 
sensation with remaining back, neck, and side pain. Past medical 
history included fractures in her lower extremities with little trau-
ma, diurnal and nocturnal enuresis, constipation, intermittent 
diarrhea, developmental delay, heterotrophic ossification with 
bilateral hip disease, scoliosis, hyperhidrosis, asthma, eczema, 
gastroesophageal reflux, hypoglycemia, vitamin D deficiency, 
headaches, and picking of the skin on her fingers.
Regarding itch experienced, the patient reported that itch 
was worse at night, even in the absence of topical skin pathology 
such as eczema, and that itching, tingling, sweating, and move-
ment of lower extremities commonly prevented her from falling 
asleep. The patient had excoriations and marks on her legs from 
scratching, and her fingers bled from picking pieces of skin. She 
used compression bandages and pressed on her lower extrem-
ities to lessen itching sensations and wore mitts to bed to pre-
vent scratching herself while asleep. The patient reported no itch 
relief from diazepam or oxycodone and only a minor benefit from 
diphenhydramine and acetaminophen. Physical examination 
revealed that the patient had a lack of position sense in the toes, 
had distal movement sense in both ankles, and detected von Frey 
0.07 g filament on the dorsum of her feet. Further examination 
with a pin showed that she had decreased sensation bilateral-
ly that was dull initially but turned painful after repeated touch. 
The patient was also diagnosed with restless legs syndrome (RLS) 
and anxiety disorder not otherwise specified. She was treated 
with cyproheptadine after reporting partial improvement of itch 
with diphenhydramine. Gabapentin was added to her treatment 
because of the reported decrease in discomfort in individuals with 
small-fiber neuropathy (32) and the reduction in lower-extremity 
movements in patients with RLS (33). Subsequently, she no lon-
ger damaged her lower-extremity skin by rubbing or scratching, 
and her evening discomfort lessened drastically, allowing lesions 
to heal. After healing, severe wounds from scratching left marks 
that resembled bruising (Figure 1A, arrows). The observation that 
no other mutations were found in patients with the NaV1.9L811P 
mutation, and that most reported patients with this mutation com-
plained of severe pruritus (31), suggests an important contribution 
of NaV1.9 to itch.
Generation and characterization of an sfGFP-tagged NaV1.9 
mouse line. To determine the expression pattern of NaV1.9, we 
used a mouse line in which the channel was fused to a fluorescent 
reporter. To limit impact on NaV1.9 function and expression, we 
(a) used superfolder green fluorescent protein (sfGFP), a gen-
eration of GFP with enhanced folding kinetics (34); (b) targeted 
the N-terminus of the channel for sfGFP fusion (17, 35); and (c) 
codon-optimized (36) sfGFP. Using the flexible accelerated Neo-
STOP tetracycline-inducible (FAST) technique (37), we inserted 
sfGFP immediately after the endogenous start codon (Figure 1B). 
The original knock-in cassette contained a construct (loxP-FRT-
Neo-STOP-FRT-tetO-loxP) that led to a global NaV1.9 knockout 
phenotype (NaV1.9–/– FAST mice). This strain had the additional 
benefit of being capable of (a) tetracycline-controlled transacti-
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we detected NaV1.9 in small to medium-sized neurons, which 
make up most nociceptors and pruriceptors (Figure 2, I and J). In 
addition, we crossed our homozygous sfGFP-NaV1.9 mice with 
NaV1.8-Cre-tdTomato mice that express the Cre recombinase 
under control of the NaV1.8 promoter to induce tdTomato fluo-
rescent protein in NaV1.8-expressing neurons (51). As a result, we 
found extensive expression overlap between NaV1.8 and NaV1.9 
(Supplemental Figure 2A). We also explored NaV1.9 expression 
in vagal ganglia responsible for transmitting stimuli from organs 
such as the heart, larynx, lungs, and alimentary tract to the cen-
tral nervous system (1). Here, we found that all NaV1.9+ neurons 
expressed the pan-neuronal marker PGP9.5 (Supplemental Fig-
tide (CGRP), indicating a subpopulation of NaV1.9+ neurons that 
are peptidergic (Figure 2D; 12%). We rarely spotted commonali-
ty of NaV1.9 with NF200, a marker for large-diameter neurons 
(Figure 2E; 1.5%). NaV1.9 has been implicated in thermal hyper-
algesia under inflammatory conditions (23, 25, 47), and we indeed 
found substantial overlap with TRPV1 (Figure 2F; 35%), a marker 
for thermosensitive nociceptor subgroups (48). However, these 
TRPV1+ cells had low NaV1.9 expression (Figure 2F, arrowheads). 
Markedly, sfGFP+ DRGs showed little to no overlap with TRPV2 
(Figure 2G; 5%). Finally, we did not observe NaV1.9 in tyrosine 
hydroxylase–expressing cells (49), which have been implicated 
in allodynia (50) (Figure 2H; 0.7%). In line with previous reports, 
Figure 1. Generation and characterization of NaV1.9 mouse lines. (A) After healing, wounds from scratching left marks that resembled bruising (black 
arrows) in the p.L811P patient. (B) Schematic diagram of the flexible accelerated Neo-STOP tetracycline-inducible (FAST) cassette illustrating the 
generation of global-knockout NaV1.9 mice (red box) and Cre-mediated expression of sfGFP-tagged NaV1.9 mice (green box). (C) A DRG section from an 
sfGFP-tagged NaV1.9 (top) and a WT mouse (bottom) showing the overlap between endogenous fluorescent signal (green) and autofluorescence, followed 
by staining with an antibody against GFP (red). (D) Western blot of DRG tissue from a WT, an sfGFP-NaV1.9, and an NaV1.9–/– mouse stained for GFP. An 
HSP90 antibody was used as a loading control. (E) Western blot of tissues taken from an sfGFP-NaV1.9 mouse and stained for GFP, stripped, and reprobed 
for NaV1.9 using a commercial antibody. An HSP90 antibody was used as a loading control. TG, trigeminal ganglia. (F and G) Representative current traces 
from ND7/23 cell lines expressing WT (black) or sfGFP-NaV1.9 (green) channels. (H–J) Current-voltage (I-V) (H) and deduced conductance-voltage (G-V)  
(I) and steady-state inactivation (SSI) (J) relationships of WT (black) and sfGFP-NaV1.9 (green). (G-V: WT-NaV1.9 V1/2 = –25.5 ± 0.5 mV, n = 16; GFP-NaV1.9 
V1/2 = –24.0 ± 0.2 mV, n = 11, P = 0.52; SSI: WT-NaV1.9 V1/2 = –29.3 ± 3.5 mV, n = 7; GFP-NaV1.9 V1/2 = –26.6 ± 1.7 mV, n = 7, P = 0.49.). Data are represented as 
mean ± SEM. Scale bar: 50 μm.
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neurons, we used MrgprA3-GFPCretdTomato/+ mice (8), in which 
MrgprA3+ neurons, which include both MrgprA3 and MrgprC11 
receptors, are labeled with tdTomato fluorescent protein. During 
patch-clamp recordings, we were able to identify NaV1.9 currents 
in all tdTomato+ DRG neurons (Figure 3, A and B). Next, we sought 
to determine coexpression of NaV1.9 with MrgprC11 using a vali-
dated antibody (54). In this case, we found that 76% of MrgprC11+ 
neurons also expressed NaV1.9 (Figure 3C). Channel expression 
was rarely observed in substance P+ cells (10%), another subset 
of neurons that have been implicated in coding for itch sensa-
tion (refs. 10, 55, and Figure 3D). Although we found NaV1.9 in a 
majority of pruriceptors thought to code for itch via members of 
the Mrgpr family, we did not see this NaV channel subtype in all 
putative itch neurons.
Loss of NaV1.9 leads to a reduction in itch. To examine the extent 
of NaV1.9 participation in itch, we carried out behavioral tests 
with our homozygous FAST mice, which contain a Neo-STOP 
ure 2B) and detected extensive expression of NaV1.9 in the jugular 
ganglia (Supplemental Figure 2C); however, we did not find cells 
with high levels of NaV1.9 expression in the nodose ganglia (Sup-
plemental Figure 2D). Finally, we determined NaV1.9 expression 
at central and peripheral ends of the DRG. The fluorescent signal 
overlaps extensively with IB4 at the inner portion of layer II of the 
dorsal horn, where connecting interneurons may be involved in 
influencing pruritic circuits (52, 53) (Figure 2K). We also observed 
extensive fluorescence along the axon of the saphenous nerve 
(Figure 2L). Although we saw strong staining for PGP9.5, we could 
not detect significant sfGFP signal at the nerve terminals of either 
the glabrous skin or the hairy skin of the mouse hind paw in whole-
mount skin preparations (Figure 2M and Supplemental Figure 2E).
NaV1.9 expression in MrgprA3/MrgprC11 neurons. The GPCRs 
MrgprA3 and MrgprC11 are expressed in a subpopulation of noci-
ceptors linked to non–histamine-related itch (10). To examine 
whether NaV1.9 is found in MrgprA3- and MrgprC11-expressing 
Figure 2. sfGFP-NaV1.9 expression patterns. (A–H) DRG sections from sfGFP-NaV1.9 mice stained for the indicated markers. TH, tyrosine hydroxylase. (I) 
Graph of cell area in DRGs with the total number of neurons by cell size (black bars), using the pan-neuronal marker PGP9.5, as well as the neurons positive 
for GFP staining (gray bars, n ≥ 200 GFP+ neurons and n ≥ 600 PGP9.5+). (J) Graph showing the fraction of neurons positive for the markers indicated that 
were also positive for GFP (n ≥ 200 neurons). (K–M) Sections of the dorsal horn stained with GFP and IB4 (K), the saphenous nerve stained with GFP and 
PGP9.5 (L), and glabrous skin of the hind paw stained with GFP and PGP9.5 (M). Panels to the right of each image (K–M) show enlarged pictures of the 
corresponding section in the white box. Scale bars: 50 μm.
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either histamine or BAM8-22 in the NaV1.9–/– mice (Figure 3, E and 
G), there appeared to be residual scratching that was delayed in 
response to CQ in the NaV1.9–/– mice compared with the littermate 
WT controls (Figure 3F). This residual scratching behavior could 
occur due to off-target effects of CQ. Indeed, Liu et al. (9) report-
ed that CQ can also activate mast cells, which may cause an itch 
behavioral response that is independent of direct MrgprA3 activa-
tion. Overall, our results support the importance of NaV1.9 in both 
histamine-dependent and histamine-independent itch.
NaV1.9 is important for histamine- and CQ-evoked Ca2+ responses. 
Histamine, CQ, and BAM8-22 are known to signal via GPCRs, with 
subsequent activation of TRP channels and increases in internal 
Ca2+ concentrations. Therefore, we wanted to determine whether 
Ca2+ responses were altered after loss of NaV1.9. We compared Ca2+ 
cassette to generate a global NaV1.9 knockout line (NaV1.9–/–), and 
we compared these results to those with WT littermate controls. 
We assessed scratching behavior in the FAST mice by subcutane-
ously injecting pruritic compounds into the nape. The number of 
bouts of hind paw scratching directed toward the injection site was 
tallied and binned every 5 minutes. Notably, our NaV1.9–/– FAST 
mice exhibited a strong reduction in acute scratching behavior 
upon histamine application (Figure 3E). Moreover, injection of 
CQ (MrgprA3 activator) and BAM8-22 (MrgprC11 activator) into 
these mice also led to a robust decrease in bouts of scratching in 
comparison with WT littermates, thereby supporting a key role for 
NaV1.9 in both histamine-dependent and histamine-independent 
itch (Figure 3, F and G). It should be noted that although there 
was no strong response throughout the 30 minutes of recording to 
Figure 3. NaV1.9 expression in MrgprA3+ and MrgprC11+ neurons and behavioral models. (A) Schematic diagram of the breeding strategy for the Mrg-
prA3-EGFP-CretdTomato/+ mice showing tdTomato signal (fluorescence was visualized directly without staining). (B) Trace showing NaV1.9 currents evoked in 
tdTomato+ neurons at the specified voltages. (C) DRG section showing the overlap between neurons stained for GFP and MrgprC11. (D) DRG section illustrat-
ing the overlap between neurons stained for GPF and substance P. (E–G) Itch assays with the indicated compound injected into the nape of the neck, record-
ed for 30-minute intervals, performed in NaV1.9
–/– mice and littermate controls for histamine (E; 8 mice per genotype, P = 0.02), CQ (F; 12 mice per genotype, 
P = 0.006), and BAM8-22 (G; WT n = 11, NaV1.9–/– n = 8, P = 0.002). Panels located directly below each graph (E–G) are the data binned and graphed for every 
5 minutes of the recording. *P < 0.05, **P < 0.01, by 2-tailed, unpaired Student’s t test. Data are represented as mean ± SEM. Scale bars: 50 μm.
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signals after the application of pruritogens in isolated DRGs from 
NaV1.9–/– and WT littermate controls using Fura-2 Ca2+ imaging. 
After the application of histamine (100 μM), we observed that the 
peak responses in NaV1.9–/– mouse DRGs were like those in WT con-
trols (WT, 42.8 ± 3.0; NaV1.9–/–, 39.8 ± 5.0; P = 0.59) (Figure 4, A and 
B). However, we found a significant reduction in the total number 
of neurons that responded to histamine in NaV1.9–/– mice compared 
with WT (WT, 8.0% ± 0.8%; NaV1.9–/–, 3.2% ± 0.6%; P = 0.0014) 
(Figure 4, A and B). Similar effects were seen with CQ (1 mM), 
with a comparable peak magnitude after the application of CQ in 
NaV1.9–/– and WT DRGs (WT, 48.2 ± 3.1; NaV1.9–/–, 44.8 ± 3.2; P = 
0.44); however, there were significantly fewer responsive neurons 
(WT, 10.1% ± 1.6%; NaV1.9–/–, 6.0% ± 0.6%; P = 0.04) (Figure 4, C 
and D). Although we did see a similar trend after BAM8-22 appli-
cation, there were no significant differences, with cells from WT 
and NaV1.9–/– mice showing a comparable magnitude in response to 
BAM8-22 (WT, 55.2 ± 15.8; NaV1.9–/–, 26.9 ± 3.7; P = 0.09) and a sim-
ilar percentage of neurons responding after compound application 
(WT, 1.1% ± 0.4%; NaV1.9–/–, 0.8% ± 0.2%; P = 0.5) (Figure 4, E and 
F). These observations highlight the importance of NaV1.9 in Ca2+ 
signaling in both histamine- and CQ-responsive neurons.
Pruritogens influence NaV1.9 currents. Next, we evaluated the 
overall electrophysiological properties of WT and NaV1.9–/– DRGs 
identified by Ca2+ imaging (Fluo-4) following a brief CQ applica-
tion and washout. Under these conditions, NaV1.9–/– DRGs exhib-
ited a depolarized shift in the resting membrane potential (RMP) 
of 8.4 ± 3.0 mV (P = 0.009) (Figure 5A). AP amplitudes and the 
threshold to elicit APs (–13.1 ± 1.8 mV in WT and –7.4 ± 3.5 mV 
in NaV1.9–/– neurons; P = 0.67) (Figure 5B) were not significantly 
affected (Table 1). AP kinetics were affected as determined by a 
higher time to reach the maximum peak (T to peak) of 0.5 ± 0.2 
milliseconds (P = 0.016) and a lower time to reach the minimum 
value in the repolarization phase (T to min) of 3.6 ± 1.2 millisec-
onds (P = 0.004) (Table 1). These results are largely in line with 
previous reports in which AP kinetics were assessed in heteroge-
neous DRG populations of NaV1.9–/– mice (22, 25). In the presence 
of CQ (100 μM), WT DRGs showed a lower amplitude of 10.4 ± 
2.7 mV (P = 0.002) and a higher AP threshold of 4.4 ± 2.4 mV (P = 
0.033), whereas the T to peak and T to min were not affected (Fig-
ure 5C and Table 1). Notably, NaV1.9–/– DRGs were not affected by 
the addition of CQ in all parameters tested (Figure 5D), suggesting 
a key role for NaV1.9 in CQ-mediated signaling.
Proinflammatory mediators such as PGE2, bradykinin, hista-
mine, and ATP can potentiate NaV1.9 currents (39), which is con-
sistent with the role of NaV1.9 in inflammatory-induced thermal 
and mechanical hyperalgesia. Therefore, we determined wheth-
er application of either histamine or MrgprA3/MrgprC11 agonist 
(CQ/BAM8-22) would also lead to increases in DRG TTX-resis-
tant (TTX-R) current density or changes in activation voltage. 
Since MrgprC11+ neurons are a subset of the MrgprA3+ population, 
we used MrgprA3-GFPCretdTomato/+ mice to isolate DRG neurons 
expressing the receptors for CQ and BAM8-22. We performed 
patch-clamp experiments in the presence of TTX (300 nM), 
which blocks all NaV channel subtypes except NaV1.8 and NaV1.9. 
Additionally, it is established that fluoride ions (F–) in the pipette 
permits the partial separation of both Na+ currents, with NaV1.9 
showing augmented currents and more hyperpolarized activation 
whereas NaV1.8 is unaffected (56). Following CQ application, we 
observed a larger current density at voltage ranges at which only 
NaV1.9 is active (Figure 6, A and B, and Table 2). Furthermore, we 
noted a 15-mV hyperpolarizing shift in channel activation volt-
age of the TTX-R Na+ current (Figure 6C). Although we saw sig-
Figure 4. Loss of NaV1.9 leads to a reduction in histamine- and CQ-responsive but not BAM8-22–responsive neurons. Fura-2 ratiometric Ca2+ imaging 
studies were performed in NaV1.9
–/– mice and littermate controls. The total percentage of responsive neurons and the magnitude of the Ca2+ response were 
quantified, and representative traces for the Ca2+ response after application of each compound are shown. For histamine, the total percentage of respon-
sive neurons was reduced (A; WT and NaV1.9–/– n ≥ 800 cells, P = 0.0014), but the magnitude of the response was the same in WT and NaV1.9–/– neurons (B; 
WT and NaV1.9
–/– n ≥ 800 cells, P = 0.59). For CQ, the percentage of responsive cells was also reduced (C; WT and NaV1.9–/– n ≥ 800 cells, P = 0.038), but the 
magnitude of the response was similar in WT and NaV1.9
–/– DRGs (D; WT and NaV1.9–/– n ≥ 800 cells, P = 0.44). For BAM8-22, no differences were observed 
for either the percentage of responsive cells (E; WT and NaV1.9–/– n ≥ 800 cells, P = 0.51) or the magnitude of the response (F; WT and NaV1.9–/– n ≥ 800 
cells, P = 0.099). *P < 0.05, **P < 0.01, by 2-tailed, unpaired Student’s t test for all data represented as mean ± SEM.
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nificantly larger NaV1.9 current density (Figure 6D), we observed 
reduced Na+ current densities at more depolarized voltages at 
which Na+ current is mainly driven by NaV1.8 (Figure 6, E and F, 
and Table 2). With the application of BAM8-22 (10 μM), we noted 
a similar potentiation in NaV1.9 current density at more hyperpo-
larized potentials (Figure 6, G, H, and J), but no significant differ-
ences in NaV1.8 current density (Figure 6, H, K, and L, and Table 
2). The application of BAM8-22 also led to an 11.5-mV hyperpolar-
ized shift in activation voltage of the TTX-R current (Figure 6I). 
Finally, CQ and BAM8-22 accelerated NaV1.9 activation but not 
NaV1.8 activation (Supplemental Figure 3).
Extensive overlap between CQ- and histamine-responsive 
neurons has been reported (9). So, we explored whether hista-
mine application (100 μM) affected TTX-R currents in MrgprA3+ 
(tdTomato+) neurons. Although we occasionally saw larger NaV1.9 
current densities, we did not find significant potentiation of NaV1.9 
or NaV1.8. However, histamine application did result in a 6.5-mV 
hyperpolarized shift of activation voltage in the TTX-R current (Fig-
ure 6, M–R). The observation that not all cells showed this effect in 
response to histamine can be explained by the population of hista-
mine-responsive neurons only partially overlapping with CQ- and 
BAM8-22–responsive cells. Therefore, it is possible that the nonre-
sponsive cells lacked the appropriate receptors for histamine.
To further assess whether CQ or BAM8-22 influenced NaV1.8 
currents, we transiently transfected mouse NaV1.8 along with 
MrgprA3 or MrgprC11 in ND7/23 cells. In cells containing NaV1.8 
and MrgprA3, we did not see altered channel activation kinetics 
after the application of CQ; however, we did observe a similar 
reduction in current densities at a range of voltages (Supple-
mental Figure 4, A and C). In cells transfected with NaV1.8 and 
MrgprC11, we noted comparable current densities and channel 
activation properties before and after application of BAM8-22 
(Supplemental Figure 4, B and D).
The NaV1.9L799P/WT mutation leads to gain of itch in mice. We 
next used a CRISPR/Cas9 strategy to introduce an orthologous 
p.L811P (c.2432T>C) gain-of-function mutation into mouse NaV1.9 
(L799P/WT; c.2396T>C) against our tetO cassette background 
(mouse and human NaV1.9 proteins are 73% identical). After 5 
backcrossings (first with the B6.C-Tg(CMV–cre)1Cgn global Cre mouse 
from The Jackson Laboratory), we performed itch assays on the 
Figure 5. APs are influenced by NaV1.9 and CQ. (A) Representative APs 
for WT (blue), NaV1.9
–/– (green), WT in the presence of CQ (100 μM, red), 
and NaV1.9
–/– mice in the presence of CQ (100 μM, purple). Dotted lines 
represent the resting membrane potential (RMP) for WT and NaV1.9
–/–: 
–40.0 ± 1.3 mV and –31.5 ± 2.7 mV, respectively (n = 13 for WT and n = 12 
for NaV1.9
–/–; **P = 0.009). (B) Quantification of AP parameters in WT and 
NaV1.9
–/– DRGs. Amplitude of AP (WT n = 16 and NaV1.9
–/– n = 20, P = 0.44) 
and threshold to elicit an AP were not affected (WT n = 20 and NaV1.9
–/–  
n = 20, P = 0.67). NaV1.9
–/– APs had a slower time to peak (T to peak; WT 
n = 17 and NaV1.9
–/– n = 20, P = 0.016) and a faster time to minimum (T to 
min; WT n = 21 and NaV1.9
–/– n = 18, P = 0.004). (C) CQ treatment affects 
the AP amplitude and threshold but not kinetics. Amplitude of AP (WT  
n = 16 and with CQ n = 16, P = 0.002) and threshold to elicit an AP (WT  
n = 20 and with CQ n = 16, P = 0.033) were significantly lower. T to peak 
(WT n = 17 and with CQ n = 17, P = 0.063) and T to min (WT n = 21 and with 
CQ n = 18, P = 0.732) were not significantly different. (D) These effects do 
not occur in NaV1.9
–/– DRGs: AP (NaV1.9
–/– n = 20 and with CQ n = 12, P = 
0.5), the threshold to elicit an AP (NaV1.9
–/– n = 20 and with CQ n = 12, P = 
0.855), T to peak (NaV1.9
–/– n = 20 and with CQ n = 12, P = 0.219), and T to 
min (NaV1.9
–/– n = 18 and with CQ n = 16, P = 0.157) were not statistically sig-
nificant. *P < 0.05, **P < 0.01, by 2-tailed, unpaired Student’s t test was 
used for RMP, and Mann-Whitney was used for all other data comparisons, 
which are represented as mean ± SEM. See Table 1 for values.
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apeutics for pathological itch 
are needed. While NaV1.9 has 
a proven role in pain (31), the 
role of this NaV channel sub-
type in itch is less understood. 
Here, we report a clinical case 
of a patient with a heterozy-
gous NaV1.9 p.L811P mutation 
who suffers from unbearable 
pruritis (Figure 1A). To better 
understand NaV1.9 involve-
ment in itch, we developed an N-terminally sfGFP-tagged NaV1.9 
mouse line. Using this mouse line, we determined that this chan-
nel subtype was expressed primarily in a subset of nonmyelinat-
ed, nonpeptidergic small-diameter DRGs that typically contain 
MrgprA3 or MrgprC11 (Figure 1B, Figures 2 and 3, and Supple-
mental Figures 1 and 2).
Our studies revealed a strong reduction in acute scratching 
behavior in NaV1.9–/– animals with itch evoked by administration 
of histamine, CQ, or BAM8-22 compared with WT controls (Figure 
4). Moreover, several AP parameters in WT DRGs were altered by 
CQ but not in the absence of NaV1.9 (Figure 5). It is noteworthy that 
NaV1.9–/– mice still scratched moderately in response to administra-
tion of CQ, a possible off-target effect of this compound. Indeed, 
Liu et al. measured CQ-induced scratching bouts in SASH mice, 
which lack mast cells, and still found a significant reduction in the 
total bouts of scratching in comparison with controls (9).
While it is challenging to extrapolate the obtained results to 
humans (22, 28, 30), NaV1.9L799P/WT mice displayed an increased 
frequency of spontaneous scratching, as is the case with human 
patients (Figure 7). Previous work has shown that this mutation 
can lead to a slowing of deactivation as well as a hyperpolarizing 
shift in channel availability, which in turn would lead to excess Na+ 
influx that can subsequently inactivate other NaV channel sub-
types to cause conduction block (22). Indeed, we found that most 
MrgprA3+ neurons from NaV1.9L799P/WT mice were unable to fire 
APs even in response to large current injections. However, a subset 
of MrgprA3+ neurons with depolarized RMPs could still fire APs in 
response to current injections as small as 10 pA, much less than 
for most WT MrgprA3+ neurons (Figure 7, I–L). Therefore, it is pos-
sible that this small subset of hyperexcitable MrgprA3+ neurons 
(~20%) may contribute to the increase in spontaneous itch seen 
in the NaV1.9L799P/WT mice and in human patients. Although other 
NaV channel subtypes, such as NaV1.7 (57) and NaV1.8 (19), may 
also be involved in transmitting pruritic stimuli, it is striking that 
loss of NaV1.9 leads to such drastic reductions in acute itch (Figure 
3). All 3 pruritic compounds potentiate NaV1.9 currents in mouse 
DRGs without affecting NaV1.8, except CQ, which influences both 
NaV1.8 and NaV1.9 currents (Figure 6 and Supplemental Figures 3 
and 4). However, BAM8-22 activity predominantly affects NaV1.9 
activation. Furthermore, CQ and BAM8-22 speed up the kinetics 
of activation of NaV1.9, making it more likely to contribute to the 
upstroke of the AP. Finally, activation of MrgprA3+ neurons with 
either of these compounds leads to significant hyperpolarized 
activation of TTX-R currents. Thus, it is conceivable that NaV1.9 
inhibitors administered to p.L811P patients can decrease itch while 
restoring, at least in part, pain sensations (22, 28). To identify such 
L799P/WT mouse line and compared the data with those obtained 
with WT NaV1.9 mice (Figure 7A). As is the case with human 
p.L811P+/WT patients, the L799P/WT mice exhibited robust spon-
taneous scratching when compared with their WT littermate con-
trols (Figure 7B). In virtual agreement with previous observations 
(22), RT-qPCR analysis of DRGs from sfGFP-NaV1.9L799P/WT mice 
revealed a 68% reduction in overall SCN11a RNA levels compared 
with levels in WT controls (Supplemental Figure 5).
Leipold et al. (22) reported a significantly depolarized RMP in 
DRGs from NaV1.9L799P/WT mice, which in turn could lead to nerve 
conduction block as other NaV channel subtypes expressed in the 
DRG would inactivate. However, it is possible that some histamine- 
and/or MrgprA3-positive DRG neurons are hyperexcitable at depo-
larized RMPs and continue to signal itch stimuli. To test this hypoth-
esis, we first measured Ca2+ responses in DRGs from NaV1.9L799P/WT 
mice and WT littermate controls in response to histamine, CQ, and 
BAM8-22. We observed no difference in the number of cells or in the 
magnitude of the Ca2+ response after the application of either hista-
mine or BAM8-22 (Figure 7, C–F). Although we did not observe a dif-
ference in the peak response after the application of CQ, we noticed 
that the percentage of responsive neurons was higher in cells from 
NaV1.9L799P/WT mice compared with WT (Figure 4, C and D, and Fig-
ure 7, G and H). The depolarized RMP caused by the mutation would 
reduce the driving force for Ca2+ entry via MrgprA3 activation. Since 
nearly all MrgprA3+ neurons express NaV1.9, it is not unreasonable to 
assume that the depolarized RMP in NaV1.9L799P/WT mice (22) pushes 
the weakly responding CQ neurons to respond more strongly.
Next, we crossed MrgprA3-EGFPCretdTomato/WT mice with 
NaV1.9L799P/WT mice to investigate the excitability of MrgprA3+ neu-
rons. The resulting mouse line allowed us to perform current-clamp 
experiments on MrgprA3+ DRGs expressing the mutant channel. 
Similar to what was reported before (22), we found a significant-
ly depolarized RMP in MrgprA3+ neurons from NaV1.9L799P/WT 
mice compared with littermate controls (WT, –40.0 ± 1.3 mV; 
mutant, –23.9 ± 1.8 mV; P = 0.0007, n = 21) (Figure 7I). Most tested 
MrgprA3+ neurons containing the mutant channel were unable to 
generate APs, even in response to large current injections (17 of 
21 cells; Figure 7K). However, a small DRG subset (4 of 21 cells) 
was able to fire at a depolarized RMP, even in response to current 
injections as low as 10 pA, and repetitive APs at 50 pA, which was 
substantially less than the current needed to evoke APs for WT 
MrgprA3+ neurons (>50 pA; Figure 7, J and L).
Discussion
While the symptom of itch is prevalent and has a substantial dis-
ease burden, it remains challenging to address. Thus, new ther-
Table 1. AP parameters of WT and NaV1.9+/MrgprA3+ neurons before and after CQ application
Amplitude of AP (mV) AP threshold (mV) AP T to peak (ms) AP T to minimum (ms)
WT 96.6 ± 2.1 (–13.1) ± 1.8 3.0 ± 0.1 14.8 ± 0.7
WT after CQ 86.2 ± 1.8B (–8.7) ± 1.5A 3.2 ± 0.1 16.5 ± 1.8
NaV1.9
–/– 90.1 ± 5.2 (–7.4) ± 3.5 3.5 ± 0.1A 11.2 ± 1.0B
NaV1.9
–/– after CQ 98.0 ± 6.1 (–9.9) ± 4.1 3.7 ± 0.1 13.5 ± 1.2
AP < 0.05 and BP <0.01, by Mann-Whitney U test for all data comparisons, which are presented as the mean ± SEM.
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by Michael Caterina (Johns Hopkins University School of Medicine, 
Baltimore, Maryland, USA). Ai9(RCL-tdTomato) mice were acquired 
from The Jackson Laboratory. All experiments were performed using 
protocols approved by the Animal Care and Use Committee of Johns 
Hopkins University School of Medicine. Two- to four-month-old male 
and female mice were backcrossed to C57BL/6J in our mouse colo-
ny for at least 5 generations. We housed 4–5 mice in each cage in the 
vivarium with a 12-hour light/12-hour dark cycle and an ad libitum 
food and water supply.
Behavioral itch assays. All mouse behavior tests were performed 
and analyzed with the experimenter blinded to genotype. Male and 
female mice (8–12 weeks old, 20–30 g each) were used for experimen-
tation. All itch behavior was performed between 8 am and 12 pm. On 
the day before the experiment, animals were placed in the test cham-
ber for 30 minutes before undergoing a series of 3 mock injections with 
5-minute breaks in between. On the day of the experiment, animals 
were allowed to acclimatize to the test chamber for 10 minutes before 
injection. Pruritic compounds were injected s.c. into the nape, and 
scratching behavior was observed for 30 minutes. A bout of scratch-
ing was defined as a continuous scratching, not wiping, movement by 
either hind paw directed at the area of the injection site. Scratching 
behavior was quantified by counting of the number of scratching bouts 
compounds, a dependable NaV1.9 cell line is of great value in drug 
screening experiments. Therefore, we developed such a tool using 
intron-mediated enhancement of gene expression, an approach 
that may also be useful to enhance heterologous expression of 
other ion channels (Figure 1, F and G). The peripherally restricted 
expression of NaV1.9 should be beneficial in limiting adverse side 
effects of therapeutics. Altogether, the insights reported here can 
help us better understand itch, and show that NaV1.9 constitutes 
an attractive pharmacological target to relieve pathological itch.
Methods
Case report and subject details. Written authorization for the release of 
health information in the case report was obtained from the patient’s 
parent (her legal guardian) in accordance with the guidelines of the 
Johns Hopkins Medicine Institutional Review Board. The patient ver-
bally assented, the parent supplied the photograph used in this publi-
cation, and the parent and patient approved the written content of the 
paragraph describing her clinical features and the layout of the picture 
showing the scars. All personal information that could lead to identifi-
cation has been removed.
Mouse lines. FAST NaV1.9 mice were generated by Ingenious Tar-
geting Laboratory (iTL) technologies. NaV1.8-Cre mice were provided 
Figure 6. Application of CQ, BAM8-22, and histamine leads to a potentiation of NaV1.9 current and a shift in activation voltage of TTX-R current. 
Voltage-clamp recordings from MrgprA3-CretdTomato/+ DRGs. (A) Sample current trace at –70 mV shows that CQ application potentiates NaV1.9 current. (B) 
Current-voltage (I-V) relationship of the TTX-resistant (TTX-R) current before and after CQ application. (C) Conductance-voltage (G-V) plot for TTX-R 
current shows a 15.7-mV hyperpolarized shift in activation voltage (n = 9, P = 0.002). (D) NaV1.9 current density (pA/pF) is higher after CQ (n = 9, P = 0.004). 
(E and F) Sample trace of NaV1.8 shows a decrease of current density after CQ administration (n = 9, P = 0.005). (G) Current trace at –70 mV shows a larger 
NaV 1.9 current density after BAM8-22. (H) I-V for TTX-R current before and after BAM8-22. (I) G-V for TTX-R current shows an 11.5-mV hyperpolarized shift 
in activation after BAM8-22 application (n = 9, P = 0.012). (J) NaV1.9 current density is higher after BAM8-22 (n = 9, P = 0.049). (K and L) NaV1.8 current and 
current density shows no differences before and after administration of BAM8-22 (n = 9, P = 0.68). (M) Current trace at –60 mV shows a moderate NaV1.9 
potentiation after histamine administration. (N) I-V for TTX-R before and after histamine administration. (O) G-V for TTX-R current after histamine shows 
a 6.5-mV hyperpolarized shift in activation voltage (n = 10, n = 0.029). (P) NaV1.9 current density shows no significant change after histamine addition  
(n = 10, P = 0.14). (Q and R) NaV1.8 current and current density shows no differences before and after histamine application (n = 9, P = 0.41). NaV1.9 and 
NaV1.8 currents before (black) and after (red) compound application are shown. *P < 0.05, **P < 0.01. A 2-tailed, unpaired and paired Student’s t test was 
used for all analyses. Data represent the mean ± SEM. See Table 2 for values.
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to settle for 30 minutes, and then the well was flooded with 500 μl of 
additional cell culture medium.
Immunofluorescence. Adult mice (8–12 weeks old) were anesthe-
tized with CO2 and perfused with 15 ml 0.1 M PBS (pH 7.4, 4°C) fol-
lowed by 25 ml of fixative (4% paraformaldehyde [vol/vol] and 14% 
saturated picric acid [vol/vol] in PBS, 4°C). Spinal cord and DRGs were 
dissected from perfused mice. DRG was postfixed in fixative at 4°C for 
30 minutes, and spinal cords were fixed for 2 hours. Skin was dissected 
from nonperfused mice and fixed in 2% paraformaldehyde (vol/vol) for 
2–4 hours at 4°C. After fixation, tissues were washed with 0.1 M PBS 3 
times for 5 minutes each. All tissues were cryoprotected in 20% sucrose 
(wt/vol) for more than 24 hours and were sectioned with a cryostat at 
20 μm for DRGs and nerves and 30 μm for spinal cord and skin. DRGs 
and nerve sections were dried at 37°C for 30 minutes. An antigen 
retrieval step was also conducted with sodium citrate (10 mM, pH 6, 
and 0.05% Tween-20) for 10 minutes at 85°C, followed by 3 washes 5 
minutes each with 0.1 M PBS. Tissue was preincubated with blocking 
solution (10% FBS [vol/vol], 0.1% Triton X-100 [vol/vol] in PBS, pH 
7.4) for 1–2 hours, and then incubated overnight at 4°C with primary 
antibodies. Secondary antibody incubation was performed for 2 hours 
in blocking solution at 22°C–23°C. Three washes with PBS (0.1% Triton 
X-100) for 5 minutes each were performed in between incubations. For 
spinal cord and skin, cryostat sections were cut to 30 μm and placed 
in 0.1 M phosphate buffer for whole-mount immunostaining. Sections 
were then incubated in blocking solution for 1 hour at room tempera-
ture. Next, sections were incubated in primary antibody overnight at 
4°C with gentle shaking for at least 24 hours. Primary incubation was 
followed by 3 washes for 5 minutes each, followed by incubation with 
secondary antibody for 2 hours at room temperature. Finally, sections 
were washed 3 more times for 5 minutes each, followed by 2 washes 
with H2O, and mounted onto coverslips. The following primary anti-
bodies were used: chicken anti-GFP (1:2,000; GFP-1020, Aves Labs), 
rabbit anti-sfGFP (1:2,000; gift from Ramanujan Hegde, University of 
Cambridge, Cambridge, United Kingdom); rabbit anti-GFP (1:2,000; 
ab290, Abcam); rabbit anti-NF200 (1:500; AB1989, Millipore); rabbit 
anti–substance P (1:1,000; AB1566, Millipore); rabbit anti–tyrosine 
hydroxylase (1:500; P40101-150, Pel-Freeze); goat anti–c-Ret (1:500; 
AF482, Novusbio); rabbit anti-PGP9.5 (1:500; PA5-29012, Thermo 
Fisher Scientific); rabbit anti-CGRP (1:500; T-4239, Peninsula Labo-
ratories); and anti-peripherin (1:200; ab4666, Abcam). To detect IB4 
binding, sections were incubated with biotinylated Griffonia simplicifo-
lia isolectin GS-IB4 (1:500; B-1205, Vector Laboratories). For second-
ary antibodies, we used donkey anti-rabbit (A31572, Alexa Fluor 555 
conjugated), goat anti-chicken (A21103, Alexa Fluor 488 conjugated), 
and rabbit anti-goat (A214310, Alexa Fluor 555 conjugated) (all from 
Thermo Fisher Scientific), and for biotinylated IB4, we used strepta-
vidin (DyLight 549, SA-5549, Vector Laboratories). All secondary anti-
bodies were diluted at 1:500 in blocking solution.
Western blot. Adult mice (8–12 weeks old) were anesthetized with 
CO2 followed by cervical dislocation. DRGs and trigeminal ganglia 
were dissected out and placed in 300 μl lysis buffer (in mM: 320 
sucrose; 10 HEPES; 2 EDTA, pH 8.0; 1.25% Triton X-100; 50 U/
ml benzonase; Roche Protease Inhibitor Mini Tablet). Tissue was 
homogenized in a 1-ml Dounce homogenizer for 5–10 minutes on ice. 
The samples were then allowed to rotate at 4°C for 1 hour. Following 
this step, tissue solution was centrifuged at 15,000 rpm for 20 min-
utes at 4°C. The supernatant with protein was removed and placed 
over the 30-minute observation period. Concentrations used for all 
compounds were 1 mM dissolved in physiological saline.
Cultures of dissociated DRG neurons. Adult mice (8–12 weeks old) 
were anesthetized with CO2 followed by cervical dislocation. The spi-
nal column was removed and trimmed of excess muscle. The vertebral 
column was then bisected, and one side was placed into a Petri dish 
with cold bicarbonate-free DMEM (bfDMEM; Thermo Fisher Scien-
tific), while the DRGs were collected from the other side. In a separate 
Petri dish, DRGs were collected into cold bfDMEM. Once all ganglia 
were collected, forceps and fine scissors were used to trim excess 
nerve roots from the ganglia. Trimmed ganglia were placed into a 
15-ml Falcon tube with 4 ml of enzyme mix for 30 minutes at 37°C. 
The enzyme mix consisted of 0.78 mg/ml of protease (Worthington) 
and 1.25 mg/ml collagenase I (Worthington) in 4 ml of bfDMEM. After 
incubation, the ganglia were centrifuged at 50 rpm for 5 minutes. The 
enzyme solution was removed, and ganglia were washed with com-
plete DMEM (10% FBS, 1× penicillin/streptomycin) and then centri-
fuged at 600 rpm. After the centrifugation step, ganglia were triturat-
ed with 1-ml pipette tips 20–30 times or until no large chunks of tissue 
remained. The dissociated cells were put through a 100-μm strainer 
(Thermo Fisher Scientific). The cells were then centrifuged for 5 min-
utes at 600 rpm. After this step, the overlying solution was removed 
and replaced with 200–400 μl or a volume of cell culture medium 
(complete DMEM, 10%FBS, 1× penicillin/streptomycin) necessary to 
drop the desired density of cells onto poly-d-lysine–coated coverslips 
in 24-well plates (Thermo Fisher Scientific). About 60–80 μl of cell 
solution was applied to the center of the coverslip. Cells were allowed 
Table 2. Influence of pruritogens on the biophysical 
characteristics of TTX-R currents in MrgprA3+ DRGs
V1/2 activation (mV) Current density (pA/pF)
TTX-R before CQ (–38.4) ± 4.8
TTX-R after CQ (–54.2) ± 3.9B
NaV1.9 before CQ (–5.6) ± 2.0
NaV1.9 after CQ (–8.1) ± 2.5
B
NaV1.8 before CQ (–26.3) ± 7.8
NaV1.8 after CQ (–4.6) ± 2.5
B
TTX-R before BAM8-22 (–32.0) ± 2.2
TTX-R after BAM8-22 (–43.5) ± 1.9A
NaV1.9 before BAM8-22 (–3.5) ± 0.6
NaV1.9 after BAM8-22 (–10.6) ± 3.3
A
NaV1.8 before BAM8-22 (–23.7) ± 4.1
NaV1.8 after BAM8-22 (–24.8) ± 4.9
TTX-R before histamine (–28.5) ± 4.8
TTX-R after histamine (–35.0) ± 4.2A
NaV1.9 before histamine (–5.0) ± 1.2
NaV1.9 after histamine (–10.3) ± 3.7
NaV1.8 before histamine (–27.8) ± 3.9
NaV1.8 after histamine (–24.3) ± 5.0
AP < 0.05 and BP< 0.01, by 2-tailed, unpaired and paired Student’s t test for 
all analyses. Data are presented as the mean ± SEM.
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as secondary antibody (Thermo Fisher Scientific). Membranes were 
incubated for 5 minutes with an enhanced chemiluminescent sub-
strate before imaging (Thermo Fisher Scientific). Primary antibodies 
used were rabbit anti-sfGFP (1:2,000; gift from Ramanujan Hegde), 
rabbit anti-NaV1.9 (1:5,000; ASC-017, Alomone Labs), and rabbit 
anti-HSP90 (1:1,000; C45G5, Cell Signaling).
Generation of ND7/23 stable cell lines. ND7/23 FRT cell lines (Sigma- 
Aldrich) were generated using the Flp-In system (Thermo Fisher Sci-
entific) per protocol instructions. For the generation of sfGFP-NaV1.9 
and NaV1.9 ND7/23 stable cell lines with intron 2 (synthesized by 
Genscript), ND7/23 FRT cells were grown to 20% confluence and 
cotransfected with the pOG44 vector (Thermo Fisher Scientific) and 
either sfGFP-NaV1.9 or NaV1.9 inserted into the pcDNA5/FRT vector 
(Thermo Fisher Scientific) at a ratio of 9:1, using the Lipofectamine 
3000 protocol (Thermo Fisher Scientific) per protocol instructions. 
Twenty-four hours after transfection, cells were washed and fresh cell 
culture medium (complete DMEM) was added. Forty-eight hours after 
transfection, the cells were split onto a fresh 6-well plate so that they 
into a new tube and stored at –20°C until further use. All other tis-
sue was placed into lysing beads (Matrix D, MP Biomedicals) in 2-ml 
tubes and kept on ice. The tubes were then placed into a benchtop 
homogenizer (FastPrep-24 Classic Instrument homogenizer, MP Bio-
medicals) and homogenized using a custom-made program (speed 
4 m/s for 20 seconds). This step was repeated if the tissue was not 
completely homogenized. The samples were then centrifuged at 
15,000 rpm for 20 minutes. Supernatant with protein was removed 
and placed into a new tube and stored at –20°C until further use. Pro-
tein concentration was determined using a BCA assay (Pierce). All 
protein samples were appropriately diluted in 1× LDS (Thermo Fisher 
Scientific) plus reducing agent (Thermo Fisher Scientific). Ten micro-
grams of protein was run on 3%–8% Tris-acetate gels (Thermo Fisher 
Scientific) with Tris-acetate running buffer and analyzed by Western 
analysis. Nitrocellulose membranes were incubated in blocking buf-
fer (5% BSA, 0.1% Tween-20, in 1× TBS) and then probed overnight 
at 4°C with appropriate primary antibodies and 2 hours at room tem-
perature with 1:10,000 goat anti-mouse HRP-conjugated antibody 
Figure 7. sfGFP-NaV1.9L799P/WT mice show higher basal scratching 
and more CQ-responsive neurons. (A) Schematic diagram show-
ing the initial cassette inserted to generate sfGFP-NaV1.9
L799P/WT  
mice and subsequent breeding to generate mice for experimen-
tation. (B) sfGFP-NaV1.9L799P/WT mice showed a higher level of 
scratching compared with their littermate controls (WT n = 8, 
sfGFP-NaV1.9
L799P/+ n = 9, P = 0.043). (C–H) Fura-2 ratiometric Ca2+ 
imaging studies were performed in sfGFP-NaV1.9
L799P/+ mice and 
littermate controls. No differences were seen after histamine 
application in either the total percentage of responsive neurons 
(C; WT and sfGFP-NaV1.9L799P/WT n ≥ 700 cells, P = 0.15) or the 
magnitude of the response (D; WT and NaV1.9–/– n ≥ 700 cells, P = 
0.36). For BAM8-22, no differences were observed for either the 
percentage of responsive cells (E; WT and sfGFP-NaV1.9L799P/WT  
n ≥ 700 cells, P = 0.19) or the magnitude of the response (F; 
WT and sfGFP-NaV1.9
L799P/WT n ≥ 700 cells, P = 0.83). For CQ, the 
percentage of responsive cells was significantly higher (G; WT and 
sfGFP-NaV1.9
L799P/WT n ≥ 700 cells, n = 0.042), but no difference 
was seen in the magnitude of the response (H; WT and sfGFP- 
NaV1.9
L799P/WT n ≥ 700 cells, P = 0.59). (I) RMPs in MrgprA3+ DRGs 
from WT (–40.0 ± 1.3 mV, n = 13) and NaV1.9
L799P/WT (–23.9 ± 1.8 mV, 
n = 21) mice differ significantly (P = 0.0007). (J–L) WT MrgprA3+ 
neurons require ≥50 pA current injection to spike (J), whereas 
MrgprA3+;NaV1.9
L799P/WT DRGs consist of a subset (17/21) that 
does not fire AP at large current injections (≥500 pA; RMP = –42 
mV) and a smaller group (4/21) that fires in response to current 
injections as low as 10 pA and repetitive APs at 50 pA (RMP = –26 
mV) (K and L). *P < 0.05 and ***P < 0.001, by 2-tailed, unpaired 
Student’s t test for Ca2+ imaging/current-clamp experiments and 
Mann-Whitney test for behavioral comparisons. Data are repre-
sented as mean ± SEM.
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For recordings, cells were allowed to equilibrate for 10 minutes 
before seals were obtained. Recordings were done 10 minutes after 
whole-cell configuration was obtained to allow dilution of cell interi-
or with the intracellular solution. Peak currents were measured using 
either 300-ms or 100-ms pulses between –100 mV and +60 mV every 
10 seconds from a holding potential of –120 mV. The peak current 
was also normalized to cell capacitance and plotted against the volt-
age to obtain current density–voltage relationships. The normalized 
G-V curves were fit with the Boltzmann function: G = 1/(1 + exp[V – 
V1/2]/k), to determine V1/2. Time to peak was obtained by measurement 
of the time from beginning of voltage step to peak current. Activation 
time constant was obtained via a single-exponential fit (Clampfit 10, 
Molecular Devices). Other data analysis software used included Mic-
rosoft Excel and Origin 8 (Originlabs). 
For current-clamp recordings, bath solutions contained (in mM): 
150 NaCl, 4 KCl, 2 CaCl2, 2 MgCl2, 10 glucose, 10 HEPES, pH 7.4 
adjusted with NaOH, 310 mOsm. Intracellular solutions contained 
(in mM): 140 K-gluconate, 13.5 NaCl, 1.6 MgCl2, 0.09 EDTA (pH 8), 
9 HEPES, 4 MgATP, 14 Tris creatine PO4, 0.3 NaGTP, pH 7.4 adjusted 
with KOH, 311 mOsm. Resting membrane potential was measured in 
I = 0 (zero current mode) for 30 seconds immediately after whole-
cell configuration was established. AP thresholds were measured 
by a series of 100-ms, 10-pA depolarizing current injections. At the 
minimal current injection needed to elicit an AP, firing threshold 
was determined by calculation of the potential at which the rate of 
rise crossed 10 V/s. Amplitude of the AP was determined as the dif-
ference between the voltage values at the peak and at the baseline 
before stimulation. Time to peak corresponded to the time between 
the threshold and the maximum peak, and time to minimum to the 
time between the maximum and the minimum value observed in the 
hyperpolarization phase. Data were analyzed offline with Clampfit 10 
and Axograph X (Molecular Devices).
RT-qPCR analysis. DRGs were extracted from 8- to 12-week-old 
mice. Total RNA was extracted from samples using RNeasy Mini Kit 
according to the manufacturer’s instructions (Qiagen). TURBO DNA-
free kit was used to remove contaminating DNA (Invitrogen). Samples 
were then converted to cDNA using SuperScript III First-Strand Syn-
thesis System for RT-PCR (Invitrogen). TaqMan primers for mouse 
SCN11a and 18S rRNA were designed and ordered from Invitrogen. 
RT-qPCR reactions consisted of 1 μl of 1:100 cDNA dilution, 5 μl 
TaqMan PCR Master Mix (Invitrogen), 0.5 μM primers, and up to 10 μl 
with deionized water. All samples were run in triplicate using Applied 
Biosystems QuantStudio 6 Flex Real-Time PCR system. The ΔΔCt 
method was used to quantify relative amounts of cDNA for each gene 
of interest normalized to 18S rRNA.
Quantification and statistical analysis. Data are presented as mean 
± SEM. “n” represents the number of samples analyzed. Statistical 
analysis was performed with 2-tailed Student’s t test, Mann-Whitney 
U test, or 1-/2-way ANOVA as indicated in the figure legends. No data 
were excluded. Differences were considered statistically significant if 
P was less than 0.05. Representative data are from experiments 
that were replicated biologically at least 3 times with similar results. 
Detailed statistical analyses are mentioned in the figure legends. Statis-
tical analysis was done with GraphPad Prism 7.04 and Microsoft Excel.
Study approval. The Animal Care and Use Committee of Johns 
Hopkins University School of Medicine approved all mouse exper-
iment protocols.
were no more than 25% confluent. After the cells were allowed to set-
tle for 2–3 hours, fresh culture medium with the appropriate amount of 
hygromycin (150 μg/ml) (Thermo Fisher Scientific) was added. Non-
transfected ND7/23 FRT cells were used as a negative control. The cell 
culture medium was replaced every 2–3 days, and the transfected cells 
could grow until no cells remained in the control plates. After this, cells 
were split and allowed to grow for an additional passage, before use 
for future experiments or freezing. Transient transfections of mouse 
NaV1.8 (NM_001205321; Origene Technologies) with either MrgprA3 
or MrgprC11 were performed with Lipofectamine 3000 (Thermo Fish-
er Scientific) per protocol instructions.
Ca2+ imaging. DRG neurons from male and female NaV1.9–/– and 
NaV1.9L799P/+ mice (8–12 weeks old) and littermate controls were dis-
sociated using an established DRG dissociation protocol (see above) 
and used for Ca2+ imaging studies within 36 hours after dissocia-
tion. All recordings and appropriate compound dilutions were done 
in modified Ringer’s solution (in mM: 140 NaCl, 5 KCl, 10 HEPES, 
2 MgCl2, 2 CaCl2, 10 glucose, pH 7.4). Neurons were loaded with 
Fura-2–acetoxymethyl ester (2.5 mM; Thermo Fisher Scientific) 
plus 0.02% Pluronic F-127 (Thermo Fisher Scientific) for 1 hour in 
the dark at 22°C. After washing twice, cells were imaged at 340- and 
380-nm excitation to detect intracellular free Ca2+. The protocol 
for all imaging experiments included a brief wash, followed by 90 
seconds of histamine (100 μM;Sigma-Aldrich), CQ (1 mM; Sigma- 
Aldrich), or BAM8-22 (10 μM; Sigma-Aldrich) application, another 
brief wash, and finally a 30-second application of high KCl (75 mM) 
to identify neurons. Cells that did not show a response to high KCl 
were discarded from our analysis. Cells were counted as respond-
ing that had a peak 340/380 ratio response 15% above baseline. All 
experiments were done in triplicate. For each compound, a total of 
700–1,000 neurons from 3 mice of the specified genotype were used 
for analysis. Analysis of the images was performed with the experi-
menter blind to the genotype.
Electrophysiological recordings of DRGs and ND7/23 cells. Pipettes 
were fabricated from borosilicate glass (A-M Instruments) and pulled 
to 1.0–2.5 MΩ using a P-1000 puller (Sutter Instruments). A multi-
clamp 700B (Molecular Devices) amplifier with pClamp 10 software 
(Molecular Devices) was used to acquire data. Series resistance for 
all cells was corrected electronically up to 70%. All recordings were 
done at room temperature. Current- and voltage-clamp recordings 
were obtained using whole-cell configurations in isolated DRGs using 
the dissociation protocol described above. Linear leak and capacitive 
transients were subtracted electronically using the –P/4 protocol. Data 
were acquired at 20 kHz and filtered at 2 kHz. Two percent agar bridg-
es filled with bath solution served as the reference electrode.
For voltage-clamp recordings, bath solutions contained (in mM): 3 
KCl, 10 glucose, 10 HEPES, 10 tetraethylammonium Cl, 40 NaCl, 90 
choline Cl, 2.5 CaCl2, 1 MgCl2, 0.05 CdCl2, pH 7.35, 308 mOsm. Intra-
cellular solutions contained (in mM): 100 CsCl, 30 CsF, 5 NaCl, 2.4 
CaCl2, 1 MgCl2, 5 EDTA (pH 8), 10 HEPES, 4 MgATP, pH 7.3, 303 mOsm. 
Osmolarity and pH were adjusted with sucrose and NaOH, respectively.
For heterologous expression of mNaV1.8 (clone obtained from 
Origene) with either MrgprA3 or GFP-MrgprC11, ND7/23 cells were 
transfected 2 days before recording with Lipofectamine 3000 (Ther-
mo Fisher Scientific) per protocol instructions. Cells transfected with 
mNaV1.8 and MrgprA3 were also cotransfected with mCherry to help 
identify successfully transfected cells.
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